Investment Summary

The BroadOak Fund and Spring Mountain Capital Invest In Genomenon

On March 16, 2021, growth capital firms The BroadOak Fund and Spring Mountain Capital invested in life science company Genomenon

Investment Highlights
  • This is The BroadOak Fund’s 10th and Spring Mountain Capital’s 6th transaction in the Life Science sector.
  • This is The BroadOak Fund’s 11th and Spring Mountain Capital’s 23rd transaction in the United States.
  • This is The BroadOak Fund’s 2nd and Spring Mountain Capital’s 1st transaction in Michigan.

Investment Summary
Date 2021-03-16
Target Genomenon
Sector Life Science
Investor(s) The BroadOak Fund
Spring Mountain Capital
Deal Type Venture

Target

Genomenon

Ann Arbor, Michigan, United States
Genomenon is an AI-driven genomics company that organizes the world’s genomic knowledge to connect patient DNA to scientific research in the diagnosis and development of treatments for patients with rare genetic diseases and cancer. Genomenon was founded in 2014 and is based in Ann Arbor, Michigan.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 2

Investor

The BroadOak Fund

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Size Small
Type Sector Focused
DESCRIPTION

The BroadOak Fund is the investment affiliate of life science focused investment bank BroadOak Capital Partners. The BroadOak Fund provides growth capital to life sciences tools and service providers that have achieved a level of commercial success. The BroadOak Fund is based in Bethesda, Maryland.

DEAL STATS #
Overall 12 of 25
Sector (Life Science) 10 of 20
Type (Venture) 5 of 7
State (Michigan) 2 of 2
Country (United States) 11 of 23
Year (2021) 1 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-06-11 Solvias

Kaiseraugst, Switzerland

Solvias is contract research, development, and manufacturing. The industries the company serves include pharmaceuticals, biotech, medical device, and cosmetics. Solvias was founded in 1999 and is based in Kaiseraugst, Switzerland.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-04-28 KromaTiD

Longmont, Colorado, United States

KromaTiD is transforming the fields of genome engineering through the discovery and characterization of genomic structural changes that help leading gene editing and pharmaceutical companies advance therapies to market. KromaTiD offers a powerful suite of products and services for studying genomic rearrangements, custom assay development services and preclinical research support in the Company's research and GLP laboratory operations. KromaTiD's proprietary Pinpoint FISH and directional Genomic Hybridization platforms (dGHTM) have applications throughout genomics, providing direct, definitive data on structural variations that no other technologies can provide. KromaTiD is base din Longmont, Colorado.

Buy -
Investor

Spring Mountain Capital

Investor Investor Investor Investor Investor

Category Growth Capital Firm
Founded 2001
Size Small
Type Sector Agnostic
DESCRIPTION

Spring Mountain Capital is a growth capital firm focused on providing expansion capital to tech-enabled companies across North America. The Firm looks to invest in earlier stage companies ($2 to $10 million of revenue) with high growth rates, proven products/services, and a path to profitability. Spring Mountain generally looks to commit $5 to $15 million per transaction. Spring Mountain Capital was formed in 2001 and is based in New York City.

DEAL STATS #
Overall 24 of 28
Sector (Life Science) 6 of 7
Type (Venture) 14 of 18
State (Michigan) 1 of 1
Country (United States) 23 of 26
Year (2021) 2 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-01-08 Oncoceutics

Philadelphia, Pennsylvania, United States

Oncoceutics, Inc. is a clinical-stage biotechnology company developing imipridones, a novel class of compounds. Oncoceutics’ lead product candidate, ONC201, has been shown in clinical testing to selectively induce cell death in multiple cancer types. ONC201 is currently in a registrational clinical trial for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected in 2021. Oncoceutics, Inc. was founded in 2009 and is based in Philadelphia, Pennsylvania.

Sell $78M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-18 180 Health Partners

Franklin, Tennessee, United States

180 Health Partners deploys teams of experienced counselors, social workers, nurses, and peer support specialists who partner with qualified providers, health plans and their expecting mothers to stabilize all aspects of their lives and support their goals for themselves and their babies. 180’s cross-functional care teams provide personalized engagement and care plans for expecting mothers to simplify the complex balance of their medical, addiction, behavioral, environmental and lifestyle needs by directly filling the gaps in care while also matching members with the best team of resources for each member’s specific journey. 180 is focused on preventing the occurrence of and/or drastically reducing the severity of NAS while also establishing a stabilized social framework for the mother’s long-term success in sobriety and motherhood.

Sell -
Mergr

Product

Company

Legal